Clinical trial NCT02333305: Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10
Official title: Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Ataxia-oculomotor Apraxia 1
Keywords: Ataxia with Oculomotor Apraxia type 1
CoQ10
hypoalbuminemia
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2015-01-07
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: coenzyme Q10
Primary purpose: TREATMENT

Brief summary: We propose a study on Ataxia with oculomotor apraxia type 1 (AOA1) in which Coenzyme Q10 (CoQ10) deficit has been observed. Main objectives of the study are :

* To monitor evolution of albumin in patients affected with AOA1 while supplemented with CoQ10 ;
* To measure with clinical scales and biological markers efficacy of supplementation on disease evolution.

AOA1 is characterised by Hypoalbuminemia. Disease duration is negatively correlated with albumin level. This study aims to understand mechanisms of the disease and our hypothesis is that correction or stabilization of albumin level with CoQ10 supplementation could impact disease evolution. The study is planned from 1 to 2 years supplementation. The CoQ10 is classified as a food supplement and has already been tested in other neurological conditions.

Detailed description: Ataxia with ocular apraxia type 1 (AOA1) is an autosomal recessive cerebellar ataxia. Patients' phenotype associates early onset cerebellar ataxia, oculomotor apraxia, neuropathy and often intellectual disability, hypoalbuminaemia and hypercholesterolemia.

APTX gene mutations responsible for AOA1 disease were identified in a family previously reported with ataxia and Coenzyme Q10 deficiency. Therefore we measured muscle Coenzyme Q10 in six patients AOA1 and found decreased levels in five. Hypercholesterolaemia and low albumin levels represent hallmarks of the disease.

We thus propose therapeutic trial with Coenzyme Q10 in AOA1 patients, by using albumin evolution as primary endpoint.

Moreover several secondary endpoints will be performed:

* clinical examination (SARA scale)
* quantitative assessments of the ataxia (with the calculation of the Composite Cerebellar Functional Severity CCFS)
* biological criteria (prealbumin, cholesterol, alphafoetoprotein, blood count, hepatic checkup)
* oculographic examination.

The study is a multicentric randomised placebo controlled trial with two-year follow-up:

* during the first year, one group will be supplemented with Coenzyme Q10 while the other group will receive a placebo;
* during the second year, all patients will be supplemented with Coenzyme Q10 in order to assess long term safety and tolerance of the treatment.

Eligibility criteria: Inclusion criteria :

* 1. Diagnosis of ataxia with oculomotor apraxia type I (AOA1) confirmed by genetic molecular analysis
* 2. Age ≥ 18 years
* 3. Hypoalbuminemia
* 4. Efficient contraception for women of childbearing potential (with pregnancy test during each visit)
* 5. Signature of the written informed consent form
* 6. Presence of a support person (for patient with cognitive disorders)

Exclusion criteria :

* 1. Hypersensitivity to one of the excipients (glycerin, ethanol, lecithin)
* 2. Absence of hypoalbuminemia
* 3. During the 2 months before inclusion :

  * Use of CoQ10
  * Treatment with antioxidants (vitamin C) and statins
  * Use of drugs affecting mitochondrial activity
  * Anti-cholesterol, thyroid hormones, anti-arrhythmic compounds, warfarin, metformin or clozapine
* 4. Treatment with vitamin E, calcium, magnesium and/or other vitamins with a concentration superior to 149 UI during more than 3 months before inclusion
* 5. Use of drugs interfering with catacholamine metabolism (reserpine, amphetamine, or inhibitors of the monoamine oxidase A, methylphenidate, cinnarizine) during the month before inclusion
* 6. Non balanced treatment with anxiolytics, hypnotics, tranquillizers and/or antidepressants during the month before inclusion
* 7. Hypothyroidism with thyroxin use
* 8. Epilepsy
* 9. Psychotic disorders
* 10. Pregnancy or lactation period
* 11. Woman of childbearing potential without efficient contraception
* 12. Participant to other therapeutic studies during the month before inclusion
* 13. Inability to receive a clear information on the research
* 14. Inability to participate to the totality of the study
* 15. Non affiliation to social security (beneficiary or assignee)
* 16. Refusal of signing the consent form

Primary outcomes:
measure: Albuminemia
timeFrame: 2 years
Secondary outcomes:
measure: SARA scale
timeFrame: 2 years
measure: CCFS
timeFrame: 2 years
measure: prealbuminemia
timeFrame: 2 years
measure: cholesterol
timeFrame: 2 years.
measure: alfa-foeto-protein
timeFrame: 2 years.
measure: Oculomotor evaluation
timeFrame: 2 years
measure: EQ5D - PHQ9
timeFrame: 2 years
Other outcomes:
Locations:
city: Paris
country: France
facility: ICM Institute
Study officials:
affiliation: Assitance Publique - Hopitaux de Paris
name: Perrine Charles, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: